美托洛尔联合曲美他嗪治疗冠心病心力衰竭患者的效果

Effects of Metoprolol combined with Trimetazidine on patients with coronary heart disease and heart failure

目的:观察美托洛尔联合曲美他嗪治疗冠状动脉粥样硬化性心脏病(冠心病)心力衰竭患者的效果。方法:选取88例冠心病心力衰竭患者为研究对象,按照随机数字表法分为对照组与观察组各44例。对照组在基础治疗基础上给予美托洛尔治疗,观察组在对照组基础上给予曲美他嗪治疗,比较两组临床疗效、心功能相关指标[左室射血分数、左室收缩末期内径、左室舒张末期内径、心率与氨基末端脑钠肽前体(NT-proBNP)]水平、炎性因子[C反应蛋白、白细胞介素-6、肿瘤坏死因子-ɑ]水平和不良反应发生率。结果:观察组治疗总有效率为97.73%,明显高于对照组的81.82%,差异有统计学意义(P<0.05);治疗后,两组左室收缩末期内径、左室舒张末期内径、心率和NT-proBNP水平均低于治疗前,且观察组低于对照组;两组左室射血分数均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05);治疗后,两组C反应蛋白、白细胞介素-6、肿瘤坏死因子-ɑ水平均低于治疗前,且观察组明显低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:美托洛尔联合曲美他嗪治疗冠心病心力衰竭患者可提高治疗总有效率,改善心功能相关指标水平,以及降低炎性因子水平,效果优于单纯美托洛尔治疗效果。

Objective:To observe effects of Metoprolol combined with Trimetazidine in treatment of patients with coronary atherosclerotic heart disease(coronary heart disease)and heart failure.Methods:88 patients with coronary heart disease and heart failure were selected as the research objects,and were divided into control group and observation group according to the random number table method,44 cases in each.Both groups took basic treatment.On this basis,the control group was given Metoprolol treatment,while the observation group was given Trimetazidine treatment on the basis of that of the control group.The clinical efficacy,heart function related indicator[left ventricular ejection fraction,left ventricular end-systolic diameter,left ventricular end-diastolic diameter,heart rate and N-terminal pro-brain natriuretic peptide(NT-proBNP)]levels,inflammatory factor[C-reactive protein,interleukin-6,tumor necrosis factor-ɑ]levels and incidence of adverse reactions were compared between the two groups.Results:The total effective rate of treatment in the observation group was 97.73%,which was significantly higher than 81.82%in the control group,and the difference was statistically significant(P<0.05).After the treatment,the left ventricular end-systolic diameters and left ventricular end-diastolic diameters of the two groups were smaller than those before the treatment,and those of the observation group were lower than those of the control group;the heart rates and NT-proBNP levels of the two groups were lower than those before the treatment,and those of the observation group were lower than those of the control group;the left ventricular ejection fractions of the two groups were higher than those before the treatment,and that of the observation group was higher than that of the control group;and the differences were statistically significant(P<0.05).After the treatment,the levels of C-reactive protein,interleukin-6,and tumor necrosis factor-ɑin the two groups were lower than those before the treatment;those of the observation group were significantly lower than those of the control group;and the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Metoprolol combined with Trimetazidine in the treatment of the patients with coronary heart disease and heart failure can increase the total effective rate of treatment,improve the levels of heart function related indicators,and reduce the levels of inflammatory factors.Moreover,it is superior to single Metoprolol.